Physician profile
Kelli Lea Leek
NPI 1780029603
$9,763.79
in general payments reported to CMS, 2019-2025
50 companies · $1,731 in 2025
The $1,731 reported for 2025 was more than what 94% of Acute Care (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $137).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $640 · 2022: $2,688 · 2023: $1,260 · 2024: $3,446 · 2025: $1,731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,137 · Travel and Lodging: $1,263 · Education: $35.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,137.26 |
| Travel and Lodging | $1,263.01 |
| Education | $35.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $2,764.19 | 2021-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $1,139.27 | 2021-2025 | |
| Emd Serono, INC. | $660.70 | 2021-2025 | Mavenclad, Mavenclad |
| Eisai INC. | $621.00 | 2022-2025 | |
| Sk Life Science, INC. | $360.25 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $334.93 | 2021-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Biogen, INC. | $329.65 | 2021-2025 | Vumerity, Tysabri, Skyclarys |
| Lilly USA, LLC | $310.95 | 2021-2025 | Kisunla, Reyvow, Emgality |
| Biohaven Pharmaceutical Holding Company Ltd. | $284.55 | 2022 | |
| Pfizer INC. | $280.82 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $263.95 | 2022-2025 | Daybue, Nuplazid |
| Ucb, INC. | $260.52 | 2022-2025 | Briviact, Nayzilam, Cimzia |
| Neurocrine Biosciences, INC. | $259.70 | 2022-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $251.69 | 2022-2025 | Vyepti, Rexulti |
| Argenx US, INC. | $157.99 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelli Leek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.